"The 10% Problem"
Less than 10% of a corporate venture's lifetime capital is deployed before the scale decision. That slice sets the direction for everything that follows. The diagnostic belongs at Stage 1 — because everything expensive comes after it.
Less than 10% of a corporate venture's total lifetime capital is deployed before the decision to scale.
Stage 0 and Stage 1 together — encompassing ideation, hypothesis work, and early customer validation — account for less than a tenth of the eventual capital consumption. In contrast, Stage 3 and Stage 4 represent 65–80% of the total investment. The direction set in that initial 10% significantly influences where the remaining 90% is allocated.
While most organizations grasp this concept mathematically, very few integrate it into their diagnostic processes.
In Stage 1, the budget typically funds workshops, design sprints, early product concepts, and executive alignment. These activities are crucial for generating ideas and fostering internal conviction. However, they often lack a structured external assessment to determine whether the organization can effectively execute what the venture requires.
As a result, Stage 1 produces a hypothesis with strong conviction but without a stress test. Stage 2 builds upon this hypothesis, and Stage 3 commits to the direction indicated by Stage 2. By the time capital is secured in Stage 3, the critical structural evaluation that should have occurred in Stage 1 is instead treated as a post-mortem.
The diagnostic process should be prioritized in Stage 1, not merely because it is cost-effective, but because the significant expenses arise afterward.